nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranolazine—Anorexia—Leflunomide—systemic scleroderma	0.00178	0.00178	CcSEcCtD
Ranolazine—Nausea—Pentoxifylline—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Ranolazine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.00177	0.00177	CcSEcCtD
Ranolazine—Vertigo—Lisinopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Ranolazine—Syncope—Lisinopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Ranolazine—Leukopenia—Lisinopril—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Ranolazine—Renal failure acute—Methotrexate—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Ranolazine—Shock—Mycophenolic acid—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Ranolazine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Ranolazine—Hypotension—Leflunomide—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Ranolazine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Ranolazine—Palpitations—Lisinopril—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Ranolazine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Ranolazine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Ranolazine—Loss of consciousness—Lisinopril—systemic scleroderma	0.00173	0.00173	CcSEcCtD
Ranolazine—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Ranolazine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Ranolazine—Cough—Lisinopril—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Ranolazine—Visual disturbance—Methotrexate—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Ranolazine—Anorexia—Mycophenolic acid—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Ranolazine—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Ranolazine—Insomnia—Leflunomide—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Ranolazine—Paraesthesia—Leflunomide—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Ranolazine—Anxiety—Lisinopril—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Ranolazine—Dyspnoea—Leflunomide—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Ranolazine—Hypotension—Mycophenolic acid—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Ranolazine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Ranolazine—Lethargy—Methotrexate—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Ranolazine—Dyspepsia—Leflunomide—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Ranolazine—Pancreatitis—Prednisone—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Ranolazine—Vomiting—Mometasone—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Ranolazine—Dry mouth—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Ranolazine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Ranolazine—Rash—Mometasone—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Ranolazine—Asthenia—Captopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ranolazine—Dermatitis—Mometasone—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ranolazine—Decreased appetite—Leflunomide—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ranolazine—Confusional state—Lisinopril—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ranolazine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Ranolazine—Headache—Mometasone—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Ranolazine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Ranolazine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Ranolazine—Fatigue—Leflunomide—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Ranolazine—Pruritus—Captopril—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Ranolazine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Ranolazine—Constipation—Leflunomide—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Ranolazine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Ranolazine—Somnolence—Mycophenolic acid—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Ranolazine—Shock—Lisinopril—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Ranolazine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Ranolazine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Ranolazine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Ranolazine—Abdominal pain—Azathioprine—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Ranolazine—Skin disorder—Lisinopril—systemic scleroderma	0.00156	0.00156	CcSEcCtD
Ranolazine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Ranolazine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Ranolazine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Ranolazine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Ranolazine—Erectile dysfunction—Prednisone—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Ranolazine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Ranolazine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00154	0.00154	CcSEcCtD
Ranolazine—Fatigue—Mycophenolic acid—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Ranolazine—Nausea—Mometasone—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Ranolazine—Anorexia—Lisinopril—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Ranolazine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Ranolazine—Constipation—Mycophenolic acid—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Ranolazine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Ranolazine—Weight decreased—Prednisone—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Ranolazine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Ranolazine—Cough—Mycophenolate mofetil—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Ranolazine—Hypotension—Lisinopril—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Ranolazine—Dizziness—Captopril—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Ranolazine—Urticaria—Leflunomide—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Ranolazine—Abdominal pain—Leflunomide—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Ranolazine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Ranolazine—Breast disorder—Methotrexate—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Ranolazine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Ranolazine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00146	0.00146	CcSEcCtD
Ranolazine—Insomnia—Lisinopril—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Ranolazine—Paraesthesia—Lisinopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Ranolazine—Vomiting—Captopril—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Ranolazine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Ranolazine—Dyspnoea—Lisinopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Ranolazine—Rash—Captopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Ranolazine—Dermatitis—Captopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Ranolazine—Somnolence—Lisinopril—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Ranolazine—Headache—Captopril—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Ranolazine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Ranolazine—Dyspepsia—Lisinopril—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Ranolazine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Ranolazine—Decreased appetite—Lisinopril—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Ranolazine—Eosinophilia—Methotrexate—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Ranolazine—Fatigue—Lisinopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Ranolazine—Shock—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Ranolazine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Ranolazine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Ranolazine—Pancreatitis—Methotrexate—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Ranolazine—Constipation—Lisinopril—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Ranolazine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Ranolazine—Bradycardia—Prednisone—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Ranolazine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Ranolazine—Nausea—Captopril—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Ranolazine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Ranolazine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Ranolazine—Asthenia—Leflunomide—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Ranolazine—Hallucination—Prednisone—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Ranolazine—Pancytopenia—Methotrexate—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Ranolazine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Ranolazine—Pruritus—Leflunomide—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Ranolazine—Connective tissue disorder—Prednisone—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Ranolazine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Ranolazine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Ranolazine—Dysuria—Methotrexate—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Ranolazine—Dizziness—Azathioprine—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Ranolazine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Ranolazine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Ranolazine—Urticaria—Lisinopril—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Ranolazine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Ranolazine—Abdominal pain—Lisinopril—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Ranolazine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Ranolazine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Ranolazine—Vomiting—Azathioprine—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Ranolazine—Eye disorder—Prednisone—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Ranolazine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Ranolazine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Ranolazine—Rash—Azathioprine—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Ranolazine—Dermatitis—Azathioprine—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Ranolazine—Headache—Azathioprine—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Ranolazine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Ranolazine—Dizziness—Leflunomide—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Ranolazine—Renal failure—Methotrexate—systemic scleroderma	0.00123	0.00123	CcSEcCtD
Ranolazine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Ranolazine—Angiopathy—Prednisone—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Ranolazine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Ranolazine—Arrhythmia—Prednisone—systemic scleroderma	0.0012	0.0012	CcSEcCtD
Ranolazine—Haematuria—Methotrexate—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Ranolazine—Vomiting—Leflunomide—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Ranolazine—Dizziness—Mycophenolic acid—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Ranolazine—Epistaxis—Methotrexate—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Ranolazine—Rash—Leflunomide—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Ranolazine—Dermatitis—Leflunomide—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Ranolazine—Mental disorder—Prednisone—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Ranolazine—Nausea—Azathioprine—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Ranolazine—Headache—Leflunomide—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Ranolazine—Malnutrition—Prednisone—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Ranolazine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Ranolazine—Asthenia—Lisinopril—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Ranolazine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00115	CcSEcCtD
Ranolazine—Pruritus—Lisinopril—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Ranolazine—Vomiting—Mycophenolic acid—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Ranolazine—Rash—Mycophenolic acid—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Ranolazine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Ranolazine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Ranolazine—Headache—Mycophenolic acid—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Ranolazine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Ranolazine—Nausea—Leflunomide—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Ranolazine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Ranolazine—Vision blurred—Prednisone—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Ranolazine—Urethral disorder—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Ranolazine—Visual impairment—Methotrexate—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Ranolazine—Angioedema—Prednisone—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Ranolazine—Dizziness—Lisinopril—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Ranolazine—Nausea—Mycophenolic acid—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Ranolazine—Vertigo—Prednisone—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Ranolazine—Eye disorder—Methotrexate—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Ranolazine—Syncope—Prednisone—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Ranolazine—Tinnitus—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Ranolazine—Cardiac disorder—Methotrexate—systemic scleroderma	0.00104	0.00104	CcSEcCtD
Ranolazine—Loss of consciousness—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Ranolazine—Vomiting—Lisinopril—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Ranolazine—Angiopathy—Methotrexate—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Ranolazine—Rash—Lisinopril—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Ranolazine—Dermatitis—Lisinopril—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Ranolazine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Ranolazine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Ranolazine—Headache—Lisinopril—systemic scleroderma	0.001	0.001	CcSEcCtD
Ranolazine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000994	0.000994	CcSEcCtD
Ranolazine—Anxiety—Prednisone—systemic scleroderma	0.00099	0.00099	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000986	0.000986	CcSEcCtD
Ranolazine—Mental disorder—Methotrexate—systemic scleroderma	0.000981	0.000981	CcSEcCtD
Ranolazine—Malnutrition—Methotrexate—systemic scleroderma	0.000975	0.000975	CcSEcCtD
Ranolazine—Nausea—Lisinopril—systemic scleroderma	0.000952	0.000952	CcSEcCtD
Ranolazine—Shock—Prednisone—systemic scleroderma	0.000937	0.000937	CcSEcCtD
Ranolazine—Nervous system disorder—Prednisone—systemic scleroderma	0.000934	0.000934	CcSEcCtD
Ranolazine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000929	0.000929	CcSEcCtD
Ranolazine—Skin disorder—Prednisone—systemic scleroderma	0.000925	0.000925	CcSEcCtD
Ranolazine—Hyperhidrosis—Prednisone—systemic scleroderma	0.00092	0.00092	CcSEcCtD
Ranolazine—Vision blurred—Methotrexate—systemic scleroderma	0.000919	0.000919	CcSEcCtD
Ranolazine—Anorexia—Prednisone—systemic scleroderma	0.000908	0.000908	CcSEcCtD
Ranolazine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000893	0.000893	CcSEcCtD
Ranolazine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000886	0.000886	CcSEcCtD
Ranolazine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000885	0.000885	CcSEcCtD
Ranolazine—Headache—Mycophenolate mofetil—systemic scleroderma	0.00088	0.00088	CcSEcCtD
Ranolazine—Vertigo—Methotrexate—systemic scleroderma	0.000876	0.000876	CcSEcCtD
Ranolazine—Leukopenia—Methotrexate—systemic scleroderma	0.000873	0.000873	CcSEcCtD
Ranolazine—Insomnia—Prednisone—systemic scleroderma	0.000861	0.000861	CcSEcCtD
Ranolazine—Paraesthesia—Prednisone—systemic scleroderma	0.000855	0.000855	CcSEcCtD
Ranolazine—Cough—Methotrexate—systemic scleroderma	0.000851	0.000851	CcSEcCtD
Ranolazine—Dyspepsia—Prednisone—systemic scleroderma	0.000838	0.000838	CcSEcCtD
Ranolazine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000834	0.000834	CcSEcCtD
Ranolazine—Decreased appetite—Prednisone—systemic scleroderma	0.000828	0.000828	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000824	0.000824	CcSEcCtD
Ranolazine—Fatigue—Prednisone—systemic scleroderma	0.000821	0.000821	CcSEcCtD
Ranolazine—Constipation—Prednisone—systemic scleroderma	0.000814	0.000814	CcSEcCtD
Ranolazine—Confusional state—Methotrexate—systemic scleroderma	0.000802	0.000802	CcSEcCtD
Ranolazine—Feeling abnormal—Prednisone—systemic scleroderma	0.000785	0.000785	CcSEcCtD
Ranolazine—Nervous system disorder—Methotrexate—systemic scleroderma	0.00078	0.00078	CcSEcCtD
Ranolazine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000779	0.000779	CcSEcCtD
Ranolazine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000779	0.000779	CcSEcCtD
Ranolazine—Skin disorder—Methotrexate—systemic scleroderma	0.000773	0.000773	CcSEcCtD
Ranolazine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000769	0.000769	CcSEcCtD
Ranolazine—Anorexia—Methotrexate—systemic scleroderma	0.000758	0.000758	CcSEcCtD
Ranolazine—Urticaria—Prednisone—systemic scleroderma	0.000756	0.000756	CcSEcCtD
Ranolazine—Abdominal pain—Prednisone—systemic scleroderma	0.000753	0.000753	CcSEcCtD
Ranolazine—Hypotension—Methotrexate—systemic scleroderma	0.000744	0.000744	CcSEcCtD
Ranolazine—Insomnia—Methotrexate—systemic scleroderma	0.00072	0.00072	CcSEcCtD
Ranolazine—Paraesthesia—Methotrexate—systemic scleroderma	0.000714	0.000714	CcSEcCtD
Ranolazine—Dyspnoea—Methotrexate—systemic scleroderma	0.000709	0.000709	CcSEcCtD
Ranolazine—Somnolence—Methotrexate—systemic scleroderma	0.000707	0.000707	CcSEcCtD
Ranolazine—Dyspepsia—Methotrexate—systemic scleroderma	0.0007	0.0007	CcSEcCtD
Ranolazine—Decreased appetite—Methotrexate—systemic scleroderma	0.000692	0.000692	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000687	0.000687	CcSEcCtD
Ranolazine—Fatigue—Methotrexate—systemic scleroderma	0.000686	0.000686	CcSEcCtD
Ranolazine—Asthenia—Prednisone—systemic scleroderma	0.000683	0.000683	CcSEcCtD
Ranolazine—Pruritus—Prednisone—systemic scleroderma	0.000674	0.000674	CcSEcCtD
Ranolazine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Ranolazine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000651	0.000651	CcSEcCtD
Ranolazine—Urticaria—Methotrexate—systemic scleroderma	0.000632	0.000632	CcSEcCtD
Ranolazine—Dizziness—Prednisone—systemic scleroderma	0.00063	0.00063	CcSEcCtD
Ranolazine—Abdominal pain—Methotrexate—systemic scleroderma	0.000629	0.000629	CcSEcCtD
Ranolazine—Vomiting—Prednisone—systemic scleroderma	0.000605	0.000605	CcSEcCtD
Ranolazine—Rash—Prednisone—systemic scleroderma	0.0006	0.0006	CcSEcCtD
Ranolazine—Dermatitis—Prednisone—systemic scleroderma	0.0006	0.0006	CcSEcCtD
Ranolazine—Headache—Prednisone—systemic scleroderma	0.000596	0.000596	CcSEcCtD
Ranolazine—Asthenia—Methotrexate—systemic scleroderma	0.000571	0.000571	CcSEcCtD
Ranolazine—Nausea—Prednisone—systemic scleroderma	0.000566	0.000566	CcSEcCtD
Ranolazine—Pruritus—Methotrexate—systemic scleroderma	0.000563	0.000563	CcSEcCtD
Ranolazine—Dizziness—Methotrexate—systemic scleroderma	0.000526	0.000526	CcSEcCtD
Ranolazine—Vomiting—Methotrexate—systemic scleroderma	0.000506	0.000506	CcSEcCtD
Ranolazine—Rash—Methotrexate—systemic scleroderma	0.000502	0.000502	CcSEcCtD
Ranolazine—Dermatitis—Methotrexate—systemic scleroderma	0.000501	0.000501	CcSEcCtD
Ranolazine—Headache—Methotrexate—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Ranolazine—Nausea—Methotrexate—systemic scleroderma	0.000473	0.000473	CcSEcCtD
